A5022764751- Glioma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Acute Myeloid Leukemia Research
- Hepatocellular Carcinoma Treatment and Prognosis
- Angiogenesis and VEGF in Cancer
- Cancer therapeutics and mechanisms
- Multiple Myeloma Research and Treatments
- DNA Repair Mechanisms
- Protein Degradation and Inhibitors
- Cancer, Hypoxia, and Metabolism
University Medical Center Hamburg-Eppendorf
2016-2021
Universität Hamburg
2016-2021
University Cancer Center Hamburg
2016-2020
Abstract The oncogene epidermal growth factor receptor variant III (EGFRvIII) is frequently expressed in glioblastomas (GBM) but its impact on therapy response still under controversial debate. Here we wanted to test if EGFRvIII influences the sensitivity towards alkylating agent temozolomide (TMZ). Therefore, retrospectively analyzed survival of 336 GBM patients, demonstrating that standard treatment, which includes TMZ, expression associated with prolonged survival, only patients...
Glioblastomas (GBM) are the most common malignant type of primary brain tumor. GBM intensively treated with surgery and combined radiochemotherapy using X-irradiation temozolomide (TMZ) but they still associated an extremely poor prognosis, urging for development new treatment strategies. To improve outcome patients, small molecule multi-kinase inhibitor sorafenib has moved into focus recent research. Sorafenib already been shown to enhance radio- radiochemosensitivity other tumor entities....
Abstract Background The oncogene epidermal growth factor receptor variant III (EGFRvIII) is expressed in approximately one-third of all glioblastomas (GBMs). So far it not clear if EGFRvIII expression induces replication stress GBM cells, which might serve as a therapeutical target. Methods Isogenetic EGFRvIII− and EGFRvIII+ cell lines with endogenous were used. Markers oncogenic such γH2AX, RPA, 53BP1, ATR, CHK1 analyzed using western blot, immunofluorescence, flow cytometry. DNA fiber...
Background: The EGF-receptor variant III (EGFRvIII) is expressed in approximately 30% of all primary glioblastoma (GBM). Although several anti-EGFRvIII strategies have already been tested, the importance EGFRvIII expression on treatment response still under debate. Our aim was to clarify relevance for GBM using uni- and multivariate analysis clinical data preclinical studies.
Despite many clinical efforts, the prognosis of GBM patients has not improved in last 10 years. Epigenetic silencing O6-methylguanine-DNA-methyltransferase (MGMT) gene is only predictive biomarker that associated with temozolomide (TMZ) response. The establishment new biomarkers, for personalized treatment significant interest. epidermal growth factor receptor (EGFR) variant III (EGFRvIII) expressed approximately 20–30% GBM. aim this study was to investigate if EGFRvIII a TMZ response by...
Abstract MGMT promoter methylation is the only accepted biomarker with prognostic role in GBM but its routine implementation limited partly response to TMZ heterogeneous, also due lack of effective alternative treatment options. Therefore, additional biomarkers are needed enable better prediction survival and improve individualized patients. A potential new epidermal growth factor receptor variant III (EGFRvIII). This constitutively activated deletion present approximately one third all IDH...